Polymyxin-based products (colistin, colistimethate sodium): realisation of the EU Commission's implementing decision
2015.01.30
Active substance: colistin | colistimethate sodium
Based on the review of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the European Commission decided on 16 December 2014 to update the product informations of medicinal products containing colistin and colistimethate.
to the risk assessment procedure (available in German only)